elisa plate coating buffer (R&D Systems)
R&D Systems is a verified supplier 
R&D Systems manufactures this product 
94
Structured Review
R&D Systems
elisa plate coating buffer
Elisa Plate Coating Buffer, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 33 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/coating+buffer/ELISA+Plate-coating+Buffer/pmc08193568-130-6-22
Average 94 stars, based on 33 article reviews
Elisa Plate Coating Buffer, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 33 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/coating+buffer/ELISA+Plate-coating+Buffer/pmc08193568-130-6-22
Average 94 stars, based on 33 article reviews
elisa plate coating buffer - by Bioz Stars,
2026-09
94/100 stars
Images
1) Product Images from "VISTA is an activating receptor in human monocytes"
Article Title: VISTA is an activating receptor in human monocytes
Journal: The Journal of Experimental Medicine
doi: 10.1084/jem.20201601
Figure Legend Snippet: Binding and specificity of novel anti-VISTA mAbs. (A) VISTA mAb1 and VISTA mAb2 binding to plate-bound recombinant human (hu) PD-L1, huB7H5, or murine (mu) B7H5 by ELISA. (B) Binding kinetics of mAb1 and mAb2 to human and murine VISTA by SPR. No binding (N.B.) was observed for mAb2 to murine VISTA. (C) Representative Biacore sensorgram plots from simultaneous binding assay with mAb1 or mAb2 captured on the surface. Antigen binding to surface mAb is shown, followed by injection of solution mAb (soln). RU, reference units. (D) Summarized FACS staining results that quantify the percentage of VISTA + cells in human whole blood. n = 6 independent donors. T N , naive T cells; T Ag-Ex , antigen-experienced T cells. (E) FACS-based median fluorescence intensity (MFI) of isotype control, mAb1, or mAb2 binding to CD14 + PBMCs while in the presence of titrated recombinant His-tagged VISTA (VISTA-His; green triangles or blue circles) or recombinant His-tagged PD-L1 (PD-L1 His; purple triangles or red squares). A–E are representative of three independent experiments.
Techniques Used: Binding Assay, Recombinant, Enzyme-linked Immunosorbent Assay, Injection, Staining, Fluorescence, Control
Figure Legend Snippet: Characterization of VISTA.COMP and PD-L1.COMP binding on human PBMCs. Related to . (A) Left unstained (gray) or stained with PD-L1.COMP (blue) or VISTA.COMP (red) protein and markers that identify immune cell subtypes, including T cells (CD3 + ), NK cells (CD56 + ), NK T cells (CD3 + CD56 + ), and monocytes (CD14 + SSC hi ) in the presence of 0.5% paraformaldehyde. FSC, forward scatter; SSC, side scatter. (B) Gating strategy for PBMC immune cell identification and T cell subtyping. (C) PD-L1.COMP and VISTA.COMP (negative control) binding to plate-bound, recombinant human (hu) PD1-Fc by ELISA. A and C were performed in two independent experiments.
Techniques Used: Binding Assay, Staining, Negative Control, Recombinant, Enzyme-linked Immunosorbent Assay
Related Articles
Binding Assay:Article Title: APOE Christchurch-mimetic therapeutic antibody reduces APOE-mediated toxicity and tau phosphorylation. Article Snippet: .. To determine the competition of 7C11 antibody with VLDLr-ApoE binding, 1 μg/mL of recombinant VLDLr (Creative BioStructure) was prepared in Article Title: APOE Christchurch‐mimetic therapeutic antibody reduces APOE‐mediated toxicity and tau phosphorylation Article Snippet: Plates were then washed four times and incubated for 45 min at RT with Horseradish Peroxidase (HRP)‐conjugated secondary antibody (1:10,000; Abcam, Cambridge, UK; Catalog No. ab97046) and 6 min with substrate reagent (R&D Systems; Catalog No. DY999) after washing the plates four times with TBSTC. .. To determine the competition of 7C11 antibody with VLDLr‐ApoE binding, 1 μg/mL of recombinant VLDLr (Creative BioStructure) was prepared in Recombinant:Article Title: APOE Christchurch-mimetic therapeutic antibody reduces APOE-mediated toxicity and tau phosphorylation. Article Snippet: .. To determine the competition of 7C11 antibody with VLDLr-ApoE binding, 1 μg/mL of recombinant VLDLr (Creative BioStructure) was prepared in Article Title: APOE Christchurch‐mimetic therapeutic antibody reduces APOE‐mediated toxicity and tau phosphorylation Article Snippet: Plates were then washed four times and incubated for 45 min at RT with Horseradish Peroxidase (HRP)‐conjugated secondary antibody (1:10,000; Abcam, Cambridge, UK; Catalog No. ab97046) and 6 min with substrate reagent (R&D Systems; Catalog No. DY999) after washing the plates four times with TBSTC. .. To determine the competition of 7C11 antibody with VLDLr‐ApoE binding, 1 μg/mL of recombinant VLDLr (Creative BioStructure) was prepared in Enzyme-linked Immunosorbent Assay:Article Title: APOE Christchurch-mimetic therapeutic antibody reduces APOE-mediated toxicity and tau phosphorylation. Article Snippet: .. To determine the competition of 7C11 antibody with VLDLr-ApoE binding, 1 μg/mL of recombinant VLDLr (Creative BioStructure) was prepared in Article Title: APOE Christchurch‐mimetic therapeutic antibody reduces APOE‐mediated toxicity and tau phosphorylation Article Snippet: Plates were then washed four times and incubated for 45 min at RT with Horseradish Peroxidase (HRP)‐conjugated secondary antibody (1:10,000; Abcam, Cambridge, UK; Catalog No. ab97046) and 6 min with substrate reagent (R&D Systems; Catalog No. DY999) after washing the plates four times with TBSTC. .. To determine the competition of 7C11 antibody with VLDLr‐ApoE binding, 1 μg/mL of recombinant VLDLr (Creative BioStructure) was prepared in Incubation:Article Title: APOE Christchurch-mimetic therapeutic antibody reduces APOE-mediated toxicity and tau phosphorylation. Article Snippet: .. To determine the competition of 7C11 antibody with VLDLr-ApoE binding, 1 μg/mL of recombinant VLDLr (Creative BioStructure) was prepared in Article Title: APOE Christchurch‐mimetic therapeutic antibody reduces APOE‐mediated toxicity and tau phosphorylation Article Snippet: Plates were then washed four times and incubated for 45 min at RT with Horseradish Peroxidase (HRP)‐conjugated secondary antibody (1:10,000; Abcam, Cambridge, UK; Catalog No. ab97046) and 6 min with substrate reagent (R&D Systems; Catalog No. DY999) after washing the plates four times with TBSTC. .. To determine the competition of 7C11 antibody with VLDLr‐ApoE binding, 1 μg/mL of recombinant VLDLr (Creative BioStructure) was prepared in Gentle:Article Title: APOE Christchurch-mimetic therapeutic antibody reduces APOE-mediated toxicity and tau phosphorylation. Article Snippet: .. To determine the competition of 7C11 antibody with VLDLr-ApoE binding, 1 μg/mL of recombinant VLDLr (Creative BioStructure) was prepared in Article Title: APOE Christchurch‐mimetic therapeutic antibody reduces APOE‐mediated toxicity and tau phosphorylation Article Snippet: Plates were then washed four times and incubated for 45 min at RT with Horseradish Peroxidase (HRP)‐conjugated secondary antibody (1:10,000; Abcam, Cambridge, UK; Catalog No. ab97046) and 6 min with substrate reagent (R&D Systems; Catalog No. DY999) after washing the plates four times with TBSTC. .. To determine the competition of 7C11 antibody with VLDLr‐ApoE binding, 1 μg/mL of recombinant VLDLr (Creative BioStructure) was prepared in Lyophilization:Article Title: AGE-breaker ALT711 reverses glycation-mediated cancer cell migration Article Snippet: .. Collagen powder was harvested from lyophilization, and BSA-AGES standard were then dissolved in the Sterility:Article Title: Surface Acoustic Wave Immunosensor for Detection of Botulinum Neurotoxin. Article Snippet: The following bioreagents were used in the work: anti-BoNT-A monoclonal antibodies specific for toxin light chain (R&D Systems, Minneapolis, MN, USA, catalog number: MAB4489, MAb), recombinant of botulinum neurotoxin type A light chain (R&D Systems, catalog number: 4489-ZN, BoNT-A LC), and bovine serum albumin (98%, Sigma-Aldrich, BSA). .. The following buffer solutions were used in work: sterile and filtered Saline:Article Title: Surface Acoustic Wave Immunosensor for Detection of Botulinum Neurotoxin. Article Snippet: The following bioreagents were used in the work: anti-BoNT-A monoclonal antibodies specific for toxin light chain (R&D Systems, Minneapolis, MN, USA, catalog number: MAB4489, MAb), recombinant of botulinum neurotoxin type A light chain (R&D Systems, catalog number: 4489-ZN, BoNT-A LC), and bovine serum albumin (98%, Sigma-Aldrich, BSA). .. The following buffer solutions were used in work: sterile and filtered Activation Assay:Article Title: Surface Acoustic Wave Immunosensor for Detection of Botulinum Neurotoxin. Article Snippet: The following bioreagents were used in the work: anti-BoNT-A monoclonal antibodies specific for toxin light chain (R&D Systems, Minneapolis, MN, USA, catalog number: MAB4489, MAb), recombinant of botulinum neurotoxin type A light chain (R&D Systems, catalog number: 4489-ZN, BoNT-A LC), and bovine serum albumin (98%, Sigma-Aldrich, BSA). .. The following buffer solutions were used in work: sterile and filtered Blocking Assay:Article Title: Surface Acoustic Wave Immunosensor for Detection of Botulinum Neurotoxin. Article Snippet: The following bioreagents were used in the work: anti-BoNT-A monoclonal antibodies specific for toxin light chain (R&D Systems, Minneapolis, MN, USA, catalog number: MAB4489, MAb), recombinant of botulinum neurotoxin type A light chain (R&D Systems, catalog number: 4489-ZN, BoNT-A LC), and bovine serum albumin (98%, Sigma-Aldrich, BSA). .. The following buffer solutions were used in work: sterile and filtered |